Supplementary Figure S3 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies

Supplementary Fig. S3. Differentiation of ML NK cells and Preactivated-Expanded CB-NK cells.